Study Details

Back to Search Results

Study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01221077

Astellas Study ID

The unique identification code given by the study sponsor.

OSI-906-207

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Non Small Cell Lung Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2011 - Sep 2014

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

88

A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Providence St. Joseph Medical Center

Burbank, United States, 91505

Chao Family Comprehensive Cancer Center - University California

Irvine, United States, 92868

Cleveland Clinic Florida

Weston, United States, 33331

Asan Medical Center

Songpa-gu, Republic of Korea, 138736

Chonnam National University Hwasun Hospital

Ilsimri, Republic of Korea, 519809

Swedish Cancer Institute

Seattle, United States, 98104

Memorial Sloan Kettering Cancer Center

New York, United States, 10021

University of Tennessee Cancer Institute

Memphis, United States, 31804

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, United States, 21231

Johns Hopkins Singapore International Medical Centre

Singapore, Singapore, 308433

Hematology Oncology Associates of the Treasure Coast

Port St. Lucie, United States, 34952

National Cancer Institute

Phayathai, Thailand, 10400

Rush University Medical Center

Chicago, United States, 60612

University of California, San Diego/Moores Cancer Center

La Jolla, United States, 92093

Juravinski Cancer Centre

Hamilton, Canada, L8V 5C2

Mount Elizabeth Medical Centre

Singapore, Singapore, 228510

Karmanos Cancer Institute

Detroit, United States, 48201

London Regional Cancer Program

London, Canada, N6A 4L6

Korea University Anam Hospital

Seoul, Republic of Korea, 136705

Medical University of South Carolina

Charleston, United States, 29425

Songklanagarind Hospital, Prince of Songkla University

Songkla, Thailand, 90110

Pacific Cancer Medical Center

Anaheim, United States, 92801

Seoul National University Bundang Hospital

Seongnam-si, Republic of Korea, 463-707

Bumrungrad Hospital Public Company, Ltd. Clinical Research Center

Bangkok, Thailand, 10110

Oncocare Cancer Center

Singapore, Singapore, 258499

Inha University Hospital

Inchon, Republic of Korea, 400711

Vanderbilt University Medical Center

Nashville, United States, 37232

Samsung Medical Center

Seoul, Republic of Korea, 135710

Princess Margaret Hospital

Toronto, Canada, M5G 2M9

Queen Mary Hospital

Pokfulam, Hong Kong

Pamela Youde Nethersole Eastern Hospital

Chai Wan, Hong Kong, 852

Monrefiore Medical Center

Bronx, United States, 10467

Khon Kaen University

Khon Kaen, Thailand, 40002

University Hospitals of Clevelnd

Cleveland, United States, 44106

Seattle Cancer Care Alliance University of Washington

Seattle, United States, 98109

Jewish General Hospital

Montreal, Canada, H3T 1E2

Gachon University Gil Medical Center

Incheon, Republic of Korea, 405760

Maharaj Nakorn Chiangmai

Chiang Mai, Thailand, 50002

H. Lee Moffitt Cancer Center and Research Institute

Tampa, United States, 33612

Northwestern Memorial Hospital

Chicago, United States, 60611

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo